Incorporating the Latest Therapeutic Strategies for HCC: Collaborating to Optimize Patient Outcomes

Watch this CME-certified on-demand Webcast of a CCO symposium at AASLD 2019 to gain expert perspectives on the evolving treatment landscape for HCC, with a focus on first-line and second-line systemic therapy for advanced/unresectable disease.
Richard S. Finn, MD
Program Director
Anthony El-Khoueiry, MD
Josep M. Llovet, MD
Andrew X. Zhu, MD, PhD, FACP
Released: January 7, 2020 Expiration: No longer available for credit

Related Content

From Clinical Care Options (CCO), download slides reviewing the integration of CAR T-cell therapy into community care

Jesús G. Berdeja, MD Caron A. Jacobson, MD Released: June 30, 2022

Experts describe key takeaways from a live symposium on HER2-, HER3-, and TROP2-targeted therapies and treatment approaches for patients, from Clinical Care Options (CCO)

Aditya Bardia, MD, MPH
Program Director
Yelena Y. Janjigian, MD Sandip P. Patel, MD
Released: June 8, 2022

Patient-reported outcomes from the HIMALAYA study of durvalumab with or without tremelimumab vs sorafenib in unresectable hepatocellular carcinoma, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 6, 2022

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for pancreatic and biliary tract cancers

Michael J. Pishvaian, MD, PhD Released: June 3, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Eisai
Exelixis
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings